CYCN - CIK 0001755237
The table below shows Cyclerion Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.18M | -$968.00K | -$1.87M | -$6.21M | -$12.84M | -$14.46M |
| Capital expenditure | $66.00K | $0.00 | - | - | - | - |
| Investing cash flow | -$66.00K | $0.00 | - | - | $0.00 | $1.46M |
| Dividends paid | - | - | - | - | - |
Cyclerion Therapeutics, Inc. reported operating cash flow of -$3.31M for fiscal year 2025. That is up 23.5% from -$4.33M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$97.50M (FY 2018) to -$3.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $825.00K | $1.38M | $0.00 | - | $0.00 | $27.00K |